Modest delays in cancer surgery due to the COVID-19 pandemic could have a significant impact on survival.
About one in four cases of colorectal cancer in patients aged 40 to 49 years meet family history-based criteria for early screening.
The American Gastroenterological Association recently published new clinical practice guidelines on the management of gastric intestinal metaplasia.
Although the use of value pathways in oncology appeared to extend time to treatment failure, it did not appear to influence overall survival.
In this interim analysis, PFS rates were compared in PD-L1–defined biomarker subsets of patients receiving maintenance durvalumab or capecitabine.
About 170 visitors and employees at Yosemite National Park have been hit by gastrointestinal illness, park officials say.
The FDA has approved Ayvakit (avapritinib; Blueprint Medicines Corporation), a tyrosine kinase inhibitor, for the treatment of adults with unresectable or metastatic gastrointestinal stromal tumor (GIST) harboring a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation, including PDGFRA D842V mutations.
Unexpectedly identifying a patient as a CDH1 carrier can lead to a “difficult conundrum” for clinicians and patients, highlighting the need for pretest counseling.
The incidence of early-onset gastric cancer has been increasing in the United States, and it seems to be distinct clinically and genetically from late-onset gastric cancer.
Continuous use of proton pump inhibitor (PPI) therapy is associated with an increased risk for acute gastroenteritis (AGE) during winter epidemic periods with peak circulation of enteric viruses.
The epidemiology of acute gastroenteritis pathogens identified from pediatric patients who have undergone allogenic hematopoietic cell transplant may be changing.
Patients with suspected eosinophilic gastrointestinal disease (EGID) in the stomach or duodenum had an increased number of mucosal mast cells with or without mucosal eosinophilia.
The researchers discovered significant differences and substantial heterogeneity in risk for GC among API subgroups. Substantial differences in all-cause survival among API subgroups were also observed.
Recommendations were developed and graded in accordance with the ESMO Clinical Practice Guidelines and subjected to an anonymous peer-review process.
Reductions in gastric cancer mortality seen with H. pylori treatment, vitamin, garlic supplementation.
Patients receiving gastric acid inhibitors have an increase in prescriptions of anti-allergic drugs.
Type 2 diabetes was linked to an increased risk for gastric cancer (adjusted hazard ratio, 1.73). Stratified statistical analysis demonstrated a significantly higher risk for gastric cardia cancer (adjusted hazard ratio, 3.40) and a significantly increased risk in those with suboptimal glycemic control (adjusted hazard ratio, 1.68).
The FDA has granted Breakthrough Therapy designation to teplizumab (PRV-031; Provention Bio), for the prevention or delay of clinical T1D in those at risk of developing the disease.
A case report suggests that endoscopic techniques may have utility in the diagnosis of the gastric involvement that can occur in follicular lymphoma.